ANCA positive relapsing polychondritis, Graves disease, and suspected moyamoya disease

A case report

Yi-Yi Xuan, MD, Tian-Fang Li, MD, PhD, Lei Zhang, MD, PhD, Sheng-Yun Liu, MD, PhD∗

Abstract

Rationale: Relapsing polychondritis (RP) is a rare and heterogeneous disease complex of unknown origin which basically affects cartilaginous structures, 40% of which accompanied by rheumatic, hematologic, and endocrine disease. Among them, vasculitis is the most common accompanying type and usually presented with positive antineutrophilic cytoplasmic antibody (ANCA). The presence of ANCA could be primary or drug-induced like propylthiouracil (PTU). Central involvement of RP is very rare, and there is almost no report of cerebral vasculopathy manifested as moyamoya.

Patient concerns: A 26-year-old woman complained about recurrent fever, auricular chondritis, ocular inflammation, and arthritis. She had an 8-year drug intake of PTU for Graves disease. Myeloperoxidase antineutrophilic cytoplasmic antibodies (MPO-ANCA) were found positive. Magnetic resonance angiography (MRA) detected multiple intracranial vasculopathy which we highly suspected it as moyamoya disease.

Diagnoses: Relapsing polychondritis, Graves disease and suspected moyamoya disease were clinically diagnosed.

Interventions and outcomes: In case of possible PTU-induced vasculitis and the aggravation of vasculopathy, PTU was replaced by Iodine-131 (I131) therapy. Induction treatment included oral prednisone 30 mg daily and oral cyclophosphamide 100 mg daily. Symptoms rapidly relieved before discharge. In admission. Prednisone was gradually tapered to 7.5 mg daily and at month 10 azathioprine was continued for maintenance.

Lessons: RP can overlap with Graves disease and moyamoya disease; comprehensive tests should be performed when admission. When relapsing polychondritis is accompanied with Graves disease, especially when ANCA is positive, PTU should be avoided.

Abbreviations: ANCA = antineutrophilic cytoplasmic antibody, MPO-ANCA = myeloperoxidase antineutrophilic cytoplasmic antibody, PTU = propylthiouracil, RP = relapsing polychondritis.

Keywords: Graves disease, moyamoya disease, MPO-ANCA, propylthiouracil, relapsing polychondritis

1. Introduction

Relapsing polychondritis (RP) is a rare disease classically characterized by recurrent inflammation of cartilaginous and proteoglycan-rich structures, which can basically affect all organs. One-third are accompanied by other rheumatic disease (common), hematologic disease, and endocrine disease (rare).[1] Central involvement of RP is very rare and commonly with severe symptoms,[1] whereas asymptomatic multiple intracranial vasculopathy manifested as moyamoya (which may later develop cerebralvascular event) has not yet been reported. Furthermore, moyamoya disease and Graves disease with RP simultaneously has barely been reported either.

Here, we report a case of RP who had a regular medication intake of propylthiouracil (PTU) for Graves disease for almost 8 years. After comprehensive examinations, we also found the presence of myeloperoxidase antineutrophilic cytoplasmic antibodies (MPO-ANCA) and cerebral involvement of asymptomatic multiple intracranial vasculopathy which we highly suspected it as moyamoya disease. As far as we know, it is an exceptionally rare occurrence of moyamoya disease and Graves disease presented in RP.

2. Case report

A 26-year-old woman was healthy until in October 2015, when both of her eyes suddenly became red, swelling, and painful. She complained about several episodes of redness and pain of auricles and eyes bilaterally for 9 months. The patient also suffered from fever and intermittent arthritis in both large and small joints including knee, wrist, elbow, hip, and metacarpophalageal joints. One week before hospitalization, she experienced another episode of pain, swelling, and redness of the left auricle. There was a past history of hyperthyroidism treated with PTU for 8 years.
Physical examinations showed the injected sclera; the red, swelling, and painful ears, both in normal shape; the swelling and tender ankles. The neurologic examination was negative.

Laboratory tests showed a raised level of erythrocyte sedimentation rate (ESR, 76 (0–20) mm/h) and C-reactive protein (CRP, 81.7 (0–10) mg/L). Immunological tests showed the presence of perinuclear-ANCA and MPO were 312.5 (0–20) RU/mL, although HLA-B27, anti-ENA antibodies (ENA, extractable nuclear antigen), and antinuclear antibodies (ANA) were negative. Serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were 5.56 (3.28–6.47) pmol/L, 16.75 (7.9–18.4) pmol/L, and 0.01 (0.34–3.6) uIU/mL, respectively. Thyroid hormone antibody (TRAB) was 5.16 (0–1.75) IU/mL. The complete metabolic panel and thorax CT scan were normal. However, the CT revealed multiple ischemic foci in the deep white matter in the left frontal lobe. Therefore, brain magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) were further performed to exclude any cerebrovascular disorders. The result showed multiple abnormalities of large blood vessels (Fig. 1).

We diagnosed ANCA positive relapsing polychondritis, suspected moyamoya disease and Graves disease. The initial treatment was prednisone (30mg/d) and oral CTX (100mg/d). PTU was withdrawn and Iodine-131 therapy was applied. At months 10, CTX was stopped and azathioprine (AZA, 50 mg/d, adjusted according to liver enzyme and white blood cell nadir) was continued for maintenance; prednisone was gradually tapered to 7.5 mg/d. At months 12, the MPO-ANCA was reexamined and decreased to 197.5 (0–20) RU/mL (Table 1). All symptoms were alleviated and inflammation markers returned to normal in 3 weeks after admission. No adverse events were observed. No flare has been found. Patient informed consent was given, and ethic committee approval is not necessary for this does not involve any animal or human trials.

### Table 1

| Follow-up          | Blood routine test | Inflammatory markers | ANCA | Thyroid test |
|--------------------|--------------------|----------------------|------|--------------|
|                    | WBC (×10⁹)        | Hb (g/L)             | PLT (×10⁹) | ESR (mm/h) | CRP (mg/L) | pANCA | MPO (RU/mL) | FT3 (pmol/L) | FT4 (pmol/L) | TSH (uIU/mL) |
| On admission       | 6.3                | 98                   | 376   | 77          | 34.98      | +      | 312.5       | 5.56         | 16.75        | 0.01         |
| 3 wk after medication | 5.55              | 124.5                | 296   | 17          | <1.5       | +      | 259.2       | 8.73         | 31.18        | 0.01         |
| 3.5 mo after medication | 7.1               | 129.4                | 243   | 11          | 6.19       | —      | —           | 5            | 13.46        | 0.05         |
| 6 mo after medication | 4.65              | 133.9                | 331   | 26          | <1.5       | +      | 215         | 3.66         | 8.46         | 0.08         |
| 10 mo after medication | 6.8               | 128.2                | 226   | 19          | <3.28      | —      | —           | 4.24         | 8.97         | 2.52         |
| 12.5 mo after medication | 7.38              | 120.2                | 206   | 18          | <1.5       | +      | 197.5       | —            | —            | —            |

**ANCA** = antineutrophil cytoplasmic antibody, **CRP** = C-reactive protein, **ESR** = erythrocyte sedimentation rate, **FT3** = free triiodothyronine, **FT4** = free thyroxine, **Hb** = hemoglobin, **MPO** = myeloperoxidase, **TSH** = thyroid stimulating hormone, **WBC** = white blood cell.

Normal values: ESR 0–20, CRP 0.00–10.00. Normal values: WBC 3.50–9.50, Hb 115.0–150.0, PLT 125–350. Normal values: FT3 3.28–6.47, FT4 7.9–18.4, TSH 0.34–5.6.

### 3. Discussion

Relapsing polychondritis, Graves disease, and suspected moyamoya disease was clinically diagnosed. First, for the cerebral vasculopathy part, the diagnosis of moyamoya disease was jointly made by a MRI physician and a neurologist after thorough discussion since the patient refused the further examination of Digital Subtraction Angiography or Computed tomography angiography. And artery biopsy was not performed concerning that it was invasive and unnecessary, so the pathologic result was uncertain. Second, the diagnosis of relapsing polychondritis was definitive according to McAdam suggested criteria.²

RP is a complex disease entity that has numerous associations with autoimmune diseases, including vasculitis, systemic lupus erythematosus, rheumatoid arthritis, and also Graves disease.¹ Although the pathophysiology of RPC still remains uncovered, Foidart et al³ found circulating antibodies against collagen components (type II, IX, XI) which may consequently cause...
inflammation and destruction of vessels and cartilages that is rich in collagen. Moreover, HLA-DR4 alleles also play a genetic role in RP which has some similarities to other rheumatic diseases.\textsuperscript{4,5} These may partly explain the overlap of the RP patient with the occurrence vasculopathy and Graves disease.

Intracranial involvement in RP is rare and severe with poor prognosis. Furthermore, cerebral involvement is mostly presumed to be caused by vasculitis\textsuperscript{6} which are often presented with positive ANCA and have symptoms like dyskinesia, sensory disability, headache, memory loss, stroke, and so forth.\textsuperscript{11} The patient only presented with imaging abnormalities for the moyamoya disease and deep white matter foci, but is still potentially risky. Kuroda et al\textsuperscript{7} reported that 20\% asymptomatic moyamoya had cerebral infarction and 40\% of them had aberrant cerebral hemodynamics, suggesting asymptomatic moyamoya disease may easily cause ischemic or hemorrhagic stroke. On the contrary, Balavoine\textsuperscript{8} reported the high prevalence of positive ANCA caused by PTU for Graves disease which varied between 4\% and 64\% with PTU (median 30\%), and young age and the duration of drug intake were the main factors contributing to the emergence of ANCA positivity. Our patient has positive ANCA and an 8-year history of PTU intake which could induce ANCA and probably cause PTU-induced cerebral vasculitis.\textsuperscript{9} Balavoine\textsuperscript{8} also stated most of them were asymptomatic, but still 15\% of them exhibited clinical evidence of vasculitis. From these 2 perspectives, 2 causes might account for the moyamoya disease: one was the vasculitis itself, and the other was the drug, PTU. Or the least possible idiopathic. Consequently, to avoid the deterioration of intracranial vasculopathy, I\textsuperscript{131} therapy was instead applied and the relatively aggressive initial treatment was adopted.

Some limitations blurred the connections for the overlapping of positive ANCA, relapsing polychondritis, PTU, and moyamoya disease. First, the biopsy result of the intracranial arteries was not obtained so that the pathology was unknown for whether it was ANCA associated or idiopathic. Second, there was no histology to support the RP although the clinical manifestation was classic. Third, the presence of ANCA was not always pathogenic in PTU-treated patients, with only 15\% of which has clinical vasculitis. And in our case, the MPO-ANCA did not rapidly improve but slowly decreased, which did not accord with the rapid improvement of ANCA after the withdrawal of PTU in some published literature.

In conclusion, RP is still a complicated disease complex that can be coexisted with moyamoya disease and Graves disease. When RP is accompanied with Graves disease, especially when ANCA is positive, PTU should be avoided.

**References**

\[1\] Cantarini L, Vitale A, Brizi MG, et al. Diagnosis and classification of relapsing polychondritis. J Autoimmun 2014;48–49:53–9.

\[2\] McAdam LP, O’Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976;55:193–215.

\[3\] Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978;299:1203–7.

\[4\] Lang B, Rothenfusser A, Lanchbury JS, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 1993;36:660–4.

\[5\] Arnaud L, Mathian A, Haroche J, et al. Pathogenesis of relapsing polychondritis: a 2013 update. Autoimmun Rev 2014;13:90–5.

\[6\] Lie JT. Classification and histopathologic spectrum of central nervous system vasculitis. Neurol Clin 1997;15:803–19.

\[7\] Kuroda S, Hashimoto N, Yoshimoto T, et al. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke 2007;38:1430–5.

\[8\] Balavoine AS, Ginoir D, Dubucquoi S, et al. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid 2015;25:1273–81.

\[9\] Chen M, Gao Y, Guo XH, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol 2012;8:476–83.